#nasdaq:advm

[marketexclusive]

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive Agreement

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive Agreement

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive AgreementItem 1.02 Termination of a Material Definitive Agreement On December 6, 2016, Adverum Biotechnologies, Inc. (the “Company”), the parent company of Annapurna Therapeutics SAS (“Annapurna”), delivered a notice to Cornell University (“Cornell”) to terminate the Amended and Restated Master Services…

View On WordPress

[marketexclusive]

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive Agreement

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive Agreement

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive AgreementItem 1.02 Termination of a Material Definitive Agreement On December 6, 2016, Adverum Biotechnologies, Inc. (the “Company”), the parent company of Annapurna Therapeutics SAS (“Annapurna”), delivered a notice to Cornell University (“Cornell”) to terminate the Amended and Restated Master Services…

View On WordPress

[marketexclusive]

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive Agreement

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive Agreement

ADVERUM BIOTECHNOLOGIES, INC. (NASDAQ:ADVM) Files An 8-K Termination of a Material Definitive AgreementItem 1.02 Termination of a Material Definitive Agreement On December 6, 2016, Adverum Biotechnologies, Inc. (the “Company”), the parent company of Annapurna Therapeutics SAS (“Annapurna”), delivered a notice to Cornell University (“Cornell”) to terminate the Amended and Restated Master Services…

View On WordPress

[marketexclusive]

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Files An 8-K

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Files An 8-K

Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today announced that former Chief Executive Officer Paul B. Cleveland has been appointed Executive Chairman of the Board and that Amber Salzman, Ph.D., formerly President and Chief Operating…

View On WordPress

[marketexclusive]

Adverum Biotechnologies Inc (NASDAQ:ADVM) Files An 8-K

Adverum Biotechnologies Inc (NASDAQ:ADVM) Files An 8-K

Adverum Biotechnologies Inc (NASDAQ:ADVM) will present at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting. The Company’s presentation materials are furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 7.01. The information furnished on this Form 8-K, including Exhibit 99.1 attached hereto,…

View On WordPress